Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Most Fully Vaccinated Patients With Cancer Have SARS-CoV-2 Antibodies

Most Fully Vaccinated Patients With Cancer Have SARS-CoV-2 Antibodies News & Analysis News From the JAMA Network Most Fully Vaccinated Patients With no covering to quantify the reduction in Zuranolone has a similar mechanism of Cancer Have SARS-CoV-2 Antibodies aerosolized particles. actionasbrexanoloneinjection,thefirstdrug In a recent study, patients undergoing can- approved specifically for PPD. Brexanolone Tracheostomy covering to reduce viral transmission cer treatment who received a COVID-19 is an infusion that is delivered continuously Virus particles mRNA vaccine produced antibodies at a over 60 hours at certified health care facili- slower rate than people without cancer, but ties and has serious risks of excessive seda- most were seropositive after the second tion or sudden loss of consciousness during dose. The results, published in JAMA Oncol- administration. In contrast, oral zuranolone ogy, reinforce the recommendation to pri- waswelltoleratedintheoutpatienttrial,with HME oritize patients with cancer for vaccination mostly mild or moderate adverse events. Blocked particles against SARS-CoV-2. Surgical mask The study, conducted in Israel, involved Guidelines for Lipid-Lowering Therapy 232patientswithcancerwithanaverageage Intensification Rarely Followed A multisite registry study involving 5000 of 66 years and a healthy, age–matched con- trol group of 261 health care workers, all of US patients showed that clinicians often don’t treat patients with atherosclerotic car- whom received Pfizer-BioNTech’s SARS- http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Most Fully Vaccinated Patients With Cancer Have SARS-CoV-2 Antibodies

JAMA , Volume 326 (9) – Sep 7, 2021

Most Fully Vaccinated Patients With Cancer Have SARS-CoV-2 Antibodies

Abstract

News & Analysis News From the JAMA Network Most Fully Vaccinated Patients With no covering to quantify the reduction in Zuranolone has a similar mechanism of Cancer Have SARS-CoV-2 Antibodies aerosolized particles. actionasbrexanoloneinjection,thefirstdrug In a recent study, patients undergoing can- approved specifically for PPD. Brexanolone Tracheostomy covering to reduce viral transmission cer treatment who received a COVID-19 is an infusion that is delivered continuously Virus...
Loading next page...
 
/lp/american-medical-association/most-fully-vaccinated-patients-with-cancer-have-sars-cov-2-antibodies-lBsijNlg3X
Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2021.14707
Publisher site
See Article on Publisher Site

Abstract

News & Analysis News From the JAMA Network Most Fully Vaccinated Patients With no covering to quantify the reduction in Zuranolone has a similar mechanism of Cancer Have SARS-CoV-2 Antibodies aerosolized particles. actionasbrexanoloneinjection,thefirstdrug In a recent study, patients undergoing can- approved specifically for PPD. Brexanolone Tracheostomy covering to reduce viral transmission cer treatment who received a COVID-19 is an infusion that is delivered continuously Virus particles mRNA vaccine produced antibodies at a over 60 hours at certified health care facili- slower rate than people without cancer, but ties and has serious risks of excessive seda- most were seropositive after the second tion or sudden loss of consciousness during dose. The results, published in JAMA Oncol- administration. In contrast, oral zuranolone ogy, reinforce the recommendation to pri- waswelltoleratedintheoutpatienttrial,with HME oritize patients with cancer for vaccination mostly mild or moderate adverse events. Blocked particles against SARS-CoV-2. Surgical mask The study, conducted in Israel, involved Guidelines for Lipid-Lowering Therapy 232patientswithcancerwithanaverageage Intensification Rarely Followed A multisite registry study involving 5000 of 66 years and a healthy, age–matched con- trol group of 261 health care workers, all of US patients showed that clinicians often don’t treat patients with atherosclerotic car- whom received Pfizer-BioNTech’s SARS-

Journal

JAMAAmerican Medical Association

Published: Sep 7, 2021

There are no references for this article.